Entecavir Dispersible Tablet for the Treatment of Chronic Hepatitis B

丁晋彪,李跃旗,周越塑,李琳,张月梅,于峰,李进

DOI: https://doi.org/10.3969/j.issn.1007-8134.2010.03.012

2010-01-01

Abstract:Objective To evaluate the efficacy and safety of entecavir dispersible tablet for the treatment of chronic hepatitis B(CHB).Methods A randomized,double-blind,double-dummy and active drug-controlled trial was performed.Totally 120 CHB patients were randomly divided into a test group(n=80) and a control group(n=40).During the first 24 weeks,the patients in the test group were administered with 0.5 mg of entecavir dispersible tablet and one tablet of dummy entecavir(Baraclude) once daily and those in the control group with 0.5 mg of entecavir and one tablet of dummy entecavir dispersible tablet once daily.Then all the patients received open-labeled entecavir dispersible tablet(0.5 mg/d) for another 24 weeks.Results Serum HBV DNA levels of the test group and the control group decreased by 4.98 and 4.73 log10 at week 12,by 5.45 and 5.00 log10 at week 24,and by 5.19 and 5.01 log10 at week 48,respectively,and the differences were not significant between the two groups.The rates of serum HBV DNA suppression(less than 1×102 U/ml) of the test group and the control group were 41.33% and 51.43% at week 12,83.10% and 74.19% at week 24 and 76.47% and 67.74% at week 48,respectively,and the differences were not significant between the two groups.Compared with the baseline levels,all the patients in both groups had a decrease(≥2 1og10) in serum HBV DNA levels at week 12 and 24,and 95.59% of the patients in the test group and all the patients in the control group had that decrease at week 48.The differences were not significant between the two groups.The rates of ALT normalization in the test group and the control group were 92.00% and 82.86% at week 12,97.18% and 93.55% at week 24,and 83.82% and 90.32% at week 48,respectively,and the differences were not significant between the two groups.No patients in the two groups had any severe adverse events.Conclusions Entecavir dispersible tablet has antiviral efficacy on CHB patients,with the same therapeutic efficacy as entecavir.It is an effective and safe agent for the treatment of CHB patients.